Aptorum Group Limited, a pharmaceutical company, develops and commercializes a range of therapeutic and diagnostic technologies to treat unmet medical needs. It focuses on developing various drug molecules and certain technologies for the treatment and diagnosis of human disease conditions in neurology, infectious diseases, gastroenterology, oncology, and other disease areas. The company also focuses on the development of surgical robotics and medical devices; and operating outpatient clinic. Aptorum Group Limited has a research and development agreement with Covar Pharmaceuticals to investigate 3 repurposed drug candidates (SACT-COV19) for coronavirus disease under existing Smart-ACT platform and Acticule infectious disease platform. Aptorum Group Limited was incorporated in 2010 and is headquartered in Hong Kong, Hong Kong.